This study (study ID PAC203 North America; PAC303 ex-North America) is evaluating 200 mg BID of pacritinib compared to physician's choice (P/C) therapy in patients with MF and severe thrombocytopenia (platelet count <50,000/μL). Approximately 399 patients in total wi...
- Primary Myelofibrosis
- Bone Marrow Diseases
- Hematologic Diseases
- Blood Platelet Disorders
- Hemorrhagic Disorders
- Splenomegaly
- Anemia
Age: 18 years - 66+
Gender: All